OR10-005 - Treatment responses in TRAPS: Eurofever/ Eurotraps by HJ Lachmann et al.
MEETING ABSTRACT Open Access
OR10-005 - Treatment responses in TRAPS:
Eurofever/ Eurotraps
HJ Lachmann*, K Minden, L Obici, A Naselli, A Insalaco, V Hentgen, R Merino, C Modesto, N Toplak, R Berendes,
R Cimaz, A Jansson, A Martini, P Woo, I Touitou, M Gattorno
From 7th Congress of International Society of Systemic Auto-Inflammatory Diseases (ISSAID)
Lausanne, Switerland. 22-26 May 2013
Introduction
TRAPS is a rare lifelong disease. Optimal treatment is
not established but tends to rely either on corticosteroids
with risks of known short and long term side effects or
anti cytokine agents which are expensive, and both types
of agents lead to higher risk of infection.
Objectives
To analyze treatments used and their responses in
patients with clinical TRAPS associated with a pathogenic
sequence variants (PSV) in TNFRSF1A enrolled in the
Eurofever/Eurotraps registry.
Methods
The Eurofever Project (agreement n 2007332, EAHC)
built a common web-based registry for all Autoinflamma-
tory diseases in collaboration with the Eurotraps Project
(FP7, HEALTH-F2-2008-200923).
Results
In total there was treatment data on 113 patients with
45 different PSV of TNFRSF1A. Patients came from 14
countries and 94.5% were of European Caucasian ancestry.
16 patients had only received symptomatic treatment.
Of 48 patients given steroids only with attacks 20
(42%) reported complete success (CR) in terminating
acute attacks but 38 (79%) were either converted to biolo-
gic therapy or had them added to improve disease control.
Of 22 patients on maintenance steroids 6 (27%) reported
complete attack prevention but 14 (64%) were converted
to biologic therapy. 37 patients received etanercept (in
the 19 where data was available for a median of 51
months). 9 patients had a CR and 26 a partial response
(PR). 10 remain on etanercept. Of the 27 who discontin-
ued etanercept inadequate disease response was sole or
contributory reason for discontinuing etanercept in 21 and
side effects in 9. 20 patients converted to anti IL-1 therapy.
38 patients received anakinra. 34 (89%) reported a CR and
4 a PR. 92% remain on anakinra with a median treatment
duration date of 23 months (range 1- 89 months).
Conclusion
This is the largest survey of treatment of TRAPS to date.
The marked predominance of patients from Western Eur-
ope may be reflected in the high use of biologic agents
which are not necessarily widely available. The most sig-
nificant findings are that corticosteroids are effective in
more than 40% of patients initially but almost 80% of
patients have been converted to anti cytokine agents.
Anakinra is completely effective in 89% of cases and con-
tinued as long-term treatment in 92%. Its use is associated
with a 90% reduction in the requirement for corticoster-
oids to treat acute attacks. Etanercept is significantly less
effective and is discontinued in almost 75% of cases.
Although these data strongly support use of anti IL-1
agents to treat TRAPS follow up remains short and re-
evaluation will be required.
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